New drug MTX-101 enters first human tests for type 1 diabetes
NCT ID NCT06324604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called MTX-101 in healthy adults and people with type 1 diabetes. The main goal is to check for side effects, see how long the drug stays in the body, and learn how it affects immune cells. About 96 participants will receive either a single dose or multiple doses of the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Health
RECRUITINGHeidelberg, Victoria, 3084, Australia
-
St Vincent's Hospital Melbourne (SVHM)
RECRUITINGFitzroy, 3065, Australia
-
The Royal Melbourne Hospital
RECRUITINGMelbourne, Victoria, 3050, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?